Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
Moxifloxacin carries an increased risk of fatal adverse effects and yet is no more effective than other fluoroquinolones. It should simply be taken off the market.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury; D005060:Europe; D024841:Fluoroquinolones; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced; D000077266:Moxifloxacin; D011008:Pneumococcal Infections / Q000188:drug therapy; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D056737:Safety-Based Drug Withdrawals; D012852:Sinusitis / Q000188:drug therapy; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced / Q000209:etiology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin